When we first launched the 21st Century Cures initiative in April, we had a pretty good idea that learning about the benefits and risks of a drug or device doesn't end when FDA initially approves or clears the product for use in certain patients with a specific disease or set of conditions.
Upton discusses the ongoing evaluation of drug and device benefits post-approval.
Share
More from Fred Upton
Mike Enzi, chairman of the Budget Committee over there in the Senate, said you got to pay for it.
I thank the chairman for yielding. This morning, I saw the news that the North Carolina Little League State championship was canceled. That is right. Why? An active shooter. I saw the frantic video of a mom holding her handheld video of…
Other voices in this conversation
